Cell Therapy News/Articles, page-8032

Repeating assumptions that are incorrect as fact.

The DSMC recommendation , to continue the trial with the current enrolment . So the trial is not futile.

Is remestemcell dead when the facts support a survival benefit of 30 + % ? NO

Is remestemcell dead when no other secondary endpoints have been assessed? No

To date, we have seen no evidence that remestemcell L could not provide a very significant survival benefit treating patients earlier or before certain other less effective drugs are used.

So in about 2 months time we may see head line results along the lines of :

Joint partners Mesoblast and Novartis announce that remestemcell shows a survival benefit of over xx% when used before y drug. We also show a reduction in ICU stay of x days further patients that received remestemcell L have less secondary heart and neurological adverse effects. We plan to make remestemcell available for EU as soon as FDA and other global regulators permit.

So until evidence shows that none of the above statement could be true, remestemcell remains a very promising therapy .

Good luck all.